Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[09/01/2018]

UCB : UCB Media Room: Cimzia label change in EU

CIMZIA® certolizumab pegol label change marks important advance for European women of childbearing age with chronic rheumatic diseaseEuropean Medicines Agency EMA has approved label change for UCB’s CIMZIA® certolizumab pegol, making it the first antiTNF for potential use in women with chronic rheumatic disease, during both pregnancy and breastfeedingData submitted to regulatory authorities... See more
 
UCB [BE0003739530/UCB]   
[08/01/2018]

UCB : UCB Media Room: Evenity EMA Filing

European Medicines Agency Accepts Filing for EVENITYTM romosozumabApplication Supported by Phase 3 Data in More Than 11,000 Postmenopausal Women and Men with Osteoporosis at Increased Risk of FractureBRUSSELS, Belgium and THOUSAND OAKS, Calif. January 8th, 2018, 07:00 AM CET – UCB Euronext Brussels: UCB and Amgen NASDAQ: AMGN today announced that the European Medicines Agency EMA has accepted... See more
 
UCB [BE0003739530/UCB]   
[20/12/2017]

UCB : UCB Media Room: bimekizumab pipeline update in PsA

Bimekizumab demonstrates impressive joint and skin responses for psoriatic arthritis patientsPositive top line results from the UCB Phase 2b BE ACTIVE study underscore the potential of bimekizumab to significantly improve joint and skin symptoms in PsA patientsThe study achieved a stringent primary endpoint, with up to 46% of psoriatic arthritis PsA patients who received bimekizumab experiencing... See more
 
UCB [BE0003739530/UCB]   
[14/12/2017]

UCB : UCB Media Room: bimekizumab pipeline update in AS

Bimekizumab advances with significant results in ankylosing spondylitis patientsPositive first results in ankylosing spondylitis from the UCB Phase 2b BE AGILE study of bimekizumab show statistical significance in multiple dose groupsThe study achieved the primary endpoint ASAS40, with up to 47% of patients receiving bimekizumab achieving at least 40% improvement in ankylosing spondylitis AS... See more
 
UCB [BE0003739530/UCB]   
[01/12/2017]

UCB : UCB Media Room: AES Curtain Raiser

UCB showcases new research and continued epilepsy leadership at the 2017 American Epilepsy Society Annual MeetingUCB reinforces commitment to delivering improved patient value by presenting latest epilepsy research findings25 scientific presentations illustrate and reinforce UCB’s dedication to improving patient value in epilepsyCongress also provides platform for collaboration, ideation and... See more